| Mitiglinide | diabetes type 2, in all types of patients | vs nateglinide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Gao, 0 | mitiglinide 10 - 20 mg three times daily | nateglinide 120 mg three times daily | Chinese type 2 diabetes mellitus patients |
| |
| Mitiglinide | | vs on top insulin glargine | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Kumashiro, 2007 | mitiglinide | on top of once daily insulin glargine | |
| |
| Mitiglinide | | vs placebo (on top pioglitazone) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Kaku, 2009 | additional mitiglinide 5 or 10 mg tid | placebo on top pioglitazone | Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy |
| |
| Nateglinide | diabetes type 2, in all types of patients | vs repaglinide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Li, 2009 | Nateglinide | repaglinide | | | Li, 2007 | nateglinide 90 mg three times daily | repaglinide 1.0 mg three times daily | Chinese patients with type 2 diabetes |
| |
| Nateglinide | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Marre, 2002 | nateglinide 60 mg, 120 mg before three meals | placebo | metformin-treated patients with HbA1c between 6.8% and 11% | | Horton, 2000 | 120 mg nateglinide before meals | placebo | patients with an HbA1c level between 6.8 and 11.0% during a 4-week placebo run-in | | Hanefeld, 1990 | nateglinide at doses of 30 mg, 60 mg, 120 mg, or 180 mg | placebo | | | Saloranta, 2002 | nateglinide (30, 60, or 120 mg, with meals). | placebo | patients with type 2 diabetes but only moderately elevated fasting plasma glucose (FPG = 7.0-8.3 mmol/liter) | | Mari, 2005 | 30, 60, or 120 mg nateglinide | placebo | mild type 2 diabetic men and women (fasting glucose 7.0-8.3 mmol/l) on diet treatment | | Goldberg, 1998 | repaglinide | placebo | type 2 diabetes | | Jovanovic, 2000 | repaglinide 1 mg or repaglinide 4 mg | placebo | | | Bech, 2003 | repaglinide initiated at 0.5 mg per meal, increased to 1 mg after 4 weeks if fasting plasma glucose exceeded 7.8 mmol/l. | placebo | pharmacotherapy-naive patients with Type 2 diabetes | | Moses, 2001 | 0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks depending on blood glucose response) | placebo | patients with type 2 diabetes considered poorly controlled by diet, but without a history of previous antidiabetic medication |
| |
| Nateglinide | | vs gliclazide (add on MET) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Ristic, 2006 | nateglinide plus metformin | gliclazide plus metformin | Patients with inadequate glucose control on maximal doses of metformin |
| |
| Repaglinide | diabetes type 2, in all types of patients | vs glibenclamide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Landgraf, 1999 | repaglinide, administered preprandially three times daily | glibenclamide, given preprandially once or twice daily | | | Marbury, 1999 | | | | | Wolffenbuttel, 1999 | repaglinide (0.5-4 mg t.i.d.) | glyburide (1.75-10.5 mg daily) | |
| |
| Repaglinide | | vs glipizide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Madsbad, 2001 | repaglinide, 1-4 mg at mealtimes | glipizide, 5-15 mg daily | |
| |
| Repaglinide | | vs metformin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Lund, 2007 | repaglinide 2 mg thrice daily | metformin 1 g twice daily | non-obese patients with type 2 diabetes |
| |
| Repaglinide | | vs on top pioglitazone | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Raskin, 2001 | | | |
| |
| Repaglinide | | vs on top rosiglitazone | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Raskin, 2001 | | | |
| |
| Repaglinide | | vs on top troglitazone | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Raskin, 2000 | repaglinide (0.5–4.0 mg at meals), | combination of repaglinide (1–4 mg at meals) and troglitazone (200–600 mg once
daily) | Patients with type 2 diabetes who
had inadequate glycemic control (HbA1c 7.0%) during previous monotherapy |
| |
| Repaglinide | | vs placebo (on top bedtime NPH-insulin) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Landin-Olsson, 1999 | | | |
| |
| Repaglinide | | vs control (add on MET) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Moses, 1999 | prestudy dose of metformin with the addition of repaglinide | prestudy dose of metformin | patients with type 2 diabetes who had inadequate glycemic control (HbA1c > 7.1%) when receiving the antidiabetic agent metformin |
| |
| Repaglinide | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Chuang, 1999 | | | | | Goldberg, 1998 | repaglinide | placebo | patients with type 2 diabetes | | Jovanovic, 2000 | repaglinide 1 mg (n = 140), or repaglinide 4 mg (n = 146) | placebo | |
| |
